The development of biomarkers involves several stages, starting from discovery to validation. Initially, potential biomarkers are identified through high-throughput screening techniques and omics technologies, such as genomics, proteomics, and metabolomics. These potential biomarkers are then rigorously tested and validated in preclinical and clinical studies to ensure they are reliable, reproducible, and specific to the exposure or effect of interest.
